FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer-Reference-Cited by-同舟云学术

FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer

Published:2022-01-17 Issue:7 Volume:34 Page:465-471
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Ay Seval¹^ORCID,Atcı Muhammed Mustafa²^ORCID,Arıkan Rukiye³^ORCID,Dülgar Özgecan¹^ORCID,Özyükseler Deniz Tataroğlu⁴^ORCID,Paksoy Nail⁵^ORCID,Doğan İzzet⁵^ORCID,Öztosun Buğra¹^ORCID,Taştekin Didem⁶^ORCID,Öven Başak Bala⁶^ORCID,Gümüş Mahmut¹^ORCID

Affiliation:

1. School of Medicine, Department of Medical Oncology, Medeniyet University, Istanbul, Turkey

2. Department of Medical Oncology, Cemil Taşcıoğlu City Hospital

3. School of Medicine, Department of Medical Oncology, Marmara University

4. Department of Medical Oncology, Istanbul Kartal Lutfi Kirdar Education and Training Hospital

5. School of Medicine, Department of Medical Oncology, Istanbul University

6. School of Medicine, Department of Medical Oncology, Bahçeşehir University

Publisher

Informa UK Limited

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology

Link